{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-159393","form_type":"8-K","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2024-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.727972+00:00","generated_at":"2026-06-01T04:51:58.355650+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Setrusumab Phase 2 data: 67% fracture rate reduction in OI at 14 months","bullets":["Median annualized fracture rate reduced 67% to 0.00 (p=0.0014, n=24) vs pre-treatment 0.72.","Lumbar spine BMD increased mean 22% at 12 months (p<0.0001, n=19); Z-score improved +1.25 (p<0.0001, n=18).","No treatment-related serious adverse events or hypersensitivity reactions reported.","Phase 3 Orbit (158 patients) and Cosmic (69 patients) studies fully enrolled."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-159393","json":"https://secwatch.observer/filing/0001193125-24-159393.json","markdown":"https://secwatch.observer/filing/0001193125-24-159393.md","text":"https://secwatch.observer/filing/0001193125-24-159393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524159393/0001193125-24-159393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524159393/d849907d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:51:58.355650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}